3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
5
Thyroid Cancer, Papillary
4
Thyroid Carcinoma, Anaplastic
2
Thyroid cancer, follicular
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Heterotaxy Syndrome
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma, Follicular
1
Interventions
Cisplatin
35
Radiotherapy
21
Magnetic Resonance Spectroscopy
19
Cetuximab
17
Specimen Handling
15
pembrolizumab
13
Carboplatin
13
Radiotherapy, Intensity-Modulated
12
Fluorouracil
12
Docetaxel
12
1,2-diaminocyclohexaneplatinum II citrate
10
Radiation
9
Platinum
9
Surgical Procedures, Operative
8
Paclitaxel
8
Drug Therapy
7
Biopsy
7
Taxes
5
Surveys and Questionnaires
5
toripalimab
4
X-Rays
4
Standard of Care
4
Fluorodeoxyglucose F18
4
Celecoxib
4
(225)Ac-DOTA-c(RGDyK)
4
cemiplimab
3
Nutritional Status
3
Laser Therapy
3
Interviews as Topic
3
Immunohistochemistry
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Laryngeal Neoplasms
×
Vemurafenib
×
Head & Neck
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled